Recently, immunotherapy has increased rapidly and has broad prospects for development.[81,82] Programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen-4, PD-L1, and PD-L2 are associated with anti-tumor immune responses. This evidence concerns the gene CTLA4 and neoplasm.